CONGRESS PRESENTATIONS
IDWeekTM 2026
Infectious Disease Week
Washington, D.C.
October 21-24, 2026
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Islek D, et al.
Association of substance use with pre-exposure prophylaxis outcomes among men who have sex with men in the United States: results from the American Men’s Internet Survey (AMIS) 2024–2025
Martinez D, et al.
Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV among Real-World Long-Acting Pre-Exposure Prophylaxis (PrEP) Users in a United States Claims Database: Updated Results from the PrEPFACTS Study
Metzner A, et al.
Real-world Persistence of Long Acting Cabotegravir for HIV Pre-Exposure Prophylaxis in the United States: Results from the PrEPFACTS Study Using Healthcare Administrative Claims Data
Metzner A, et al.
User Experience Concepts Assessed Among People in the United States Using Long-Acting Injectable Cabotegravir for PrEP in Real-World Care: Results from the CAPTIVATE Study
Mounzer K, et al.
Low Rate of HIV Acquisition on Cabotegravir Pre-Exposure Prophylaxis in OPERA: Three Out of Six Had Possible Long-Acting Early Viral Inhibition
Pilgrim N, et al.
Early Expectations of Cabotegravir Every 4 Month Injections for HIV Pre-Exposure Prophylaxis among Individuals Using Cabotegravir Every 2 Month Injectable
Swygard H, et al.
Racial and Ethnic Differences in Long Acting Cabotegravir for HIV-1 Pre-Exposure Prophylaxis Experience in a US Real-World Cross‑Sectional Study: Results from the CAPTIVATE Study
-
Cabotegravir Treatment
Gandhi M, et al.
Real-World Virologic Effectiveness Outcomes with Long-Acting Cabotegravir plus Rilpivirine in People Who are Treatment-Experienced with Viremia: A Systematic Literature Review
Hsu RK, et al.
High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort
Short WR, et al.
Real-world Outcomes with Long-Acting Cabotegravir plus Rilpivirine in People with High Body Mass Index: A Systematic Literature Review
-
Dolutegravir-based Regimens
Boulos J, et al.
Dolutegravir + Lamivudine in People with HIV-1 Who Are Naive to Antiretroviral Therapy with Baseline Viral Load ≥500,000 c/mL: Systematic Literature Review and Meta-Analysis of Real-World Evidence
Pierone G, et al.
Virologic Outcomes of Individuals Prescribed Dolutegravir/Lamivudine After an Oral Antiretroviral Therapy Treatment Interruption: Findings from the OPERA Cohort
Short W, et al.
Antiretroviral Safety in Pregnancy: An Updated Analysis of Prospective Reports from the Antiretroviral Pregnancy Registry
-
Fostemsavir
-
Pipeline
-
Other Disease-Related Content
Fraysse J, et al.
Modelling the Future Epidemiological and Economic Burden of HIV in the United States: Substantial New Diagnoses and Additional Costs Projected Under Current Care Patterns
Fraysse J, et al.
Modelling the impact of scale-up of long-acting injectables for HIV prevention and treatment in the United States (US)
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
-
Cabotegravir Treatment
Buzon-Martin L, et al.
Long-Term Durability and Virological Effectiveness of Long-Acting Cabotegravir plus Rilpivirine in Routine HIV Care: Updated Real-World Data from the Spanish RELATIVITY Cohort
Buzon-Martin L, et al.
Longitudinal Adherence to Long-Acting Cabotegravir plus Rilpivirine in Routine Clinical Practice: Updated Temporal Trends from the RELATIVITY Cohort in Spain
Buzon-Martin L, et al.
Switching to Long-Acting Cabotegravir and Rilpivirine Without Historical Genotyping Availability: Effectiveness and Durability from the RELATIVITY Cohort
Estes A, et al.
Predictors of Successful Switch to Long-Acting Cabotegravir/Rilpivirine in a National Veterans Health Administration Cohort
Jones M, et al.
Long-Term Outcomes of Cabotegravir-Rilpivirine Long-Acting Injectable Initiated in People with HIV with Recent Viremia: A National VHA Cohort Study
Nkodo ENS, et al.
Advancing Urban-Rural Equity in the Delivery of Long-acting Injectable Antiretroviral Therapy: Preliminary Results of the IM-CAPABLE Study
Troya J, et al.
Beyond Viral Suppression: Immunologic Evolution After Switching to Long-Acting Cabotegravir Plus Rilpivirine in Real-World Practice
Troya J, et al.
Long-Acting Cabotegravir plus Rilpivirine in People With HIV Aged ≥60 Years: Real-World Evidence From the RELATIVITY Cohort in the Context of Multimorbidity
Troya J, et al.
Long-Acting Cabotegravir Plus Rilpivirine in People With HIV With Obesity (BMI ≥30 kg/m²): High Durability With Distinct Discontinuation Patterns
Wilson B, et al.
Persistence and Virologic Outcomes at 12 Months After Switch to Long-Acting Cabotegravir-Rilpivirine in Veterans With HIV: A Nationwide Matched Cohort Study
-
Dolutegravir-based Regimens
-
Fostemsavir
-
